Optimizing the Personalized Care for the Management of Rectal Cancer: A Consensus Statement

Yıl: 2022 Cilt: 33 Sayı: 8 Sayfa Aralığı: 627 - 663 Metin Dili: İngilizce DOI: 10.5152/tjg.2022.211103 İndeks Tarihi: 09-10-2022

Optimizing the Personalized Care for the Management of Rectal Cancer: A Consensus Statement

Öz:
Colorectal cancer is the third most common cancer in Turkey. The current guidelines do not provide sufficient information to cover all aspects of the management of rectal cancer. Although treatment has been standardized in terms of the basic principles of neoadjuvant, surgical, and adjuvant therapy, uncertainties in the management of rectal cancer may lead to significant differences in clinical practice. In order to clarify these uncertainties, a consensus program was constructed with the participation of the physicians from the Acıbadem Mehmet Ali Aydınlar and Koç Universities. This program included the physicians from the departments of general surgery, gastroenterology, pathology, radiology, nuclear medicine, medical oncology, radiation oncology, and medical genetics. The gray zones in the management of rectal cancer were determined by reviewing the evidence-based data and current guidelines before the meeting. Topics to be discussed consisted of diagnosis, staging, surgical treatment for the primary disease, use of neoadjuvant and adjuvant treatment, management of recurrent disease, screening, follow-up, and genetic counseling. All those topics were discussed under supervision of a presenter and a chair with active participation of related physicians. The consensus text was structured by centralizing the decisions based on the existing data.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık
  • 1. Turkiye kanser Istatistikleri; 2015. Available at: https://hsgm.saglik. gov.tr/tr/kanser-istatistikleri/yillar/2015-yili-turkiye-kanser-istatistikleri. html
  • 2. Tatar M, Tatar F. Colorectal cancer in Turkey: current situation and challenges for the future. Eur J Health Econ. 2010;10(suppl 1):S99- S105. [CrossRef]
  • 3. McGuire S. World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015. Adv Nutr. 2016;7(2):418-419. [CrossRef]
  • 4. WHO. Cancer Fact sheet; 2018. Available at: http: //www .who. int/ e n/new s-roo m/fac t-she ets/d etail /canc er.
  • 5. Balmaña J, Balaguer F, Cervantes A, Arnold D, ESMO Guidelines Working Group. Familial risk-colorectal cancer: ESMO Clinical Practice Guidelines. Ann Oncol. 2013;24(suppl 6):vi73-vi80. [CrossRef]
  • 6. Garborg K, Holme Ø, Løberg M, Kalager M, Adami HO, Bretthauer M. Current status of screening for colorectal cancer. Ann Oncol. 2013;24(8):1963-1972. [CrossRef]
  • 7. Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, Bardelli A. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst. 2009;101(19):1308-1324. [CrossRef]
  • 8. Tanaka A, Sadahiro S, Suzuki T, Okada K, Saito G. Comparisons of rigid proctoscopy, flexible colonoscopy, and digital rectal examination for determining the localization of rectal cancers. Dis Colon Rectum. 2018;61(2):202-206. [CrossRef]
  • 9. Sehgal V, Krishnan B, McCulloch G, Besherdas K. PTU-263 Is it time for gastroenterology and general medicine to go their separate ways? Gut. 2012;61(Suppl 2):A293.2-A2A294. [CrossRef]
  • 10. Locker GY, Hamilton S, Harris J, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol. 2006;24(33):5313-5327. [CrossRef]
  • 11. Duffy MJ, Lamerz R, Haglund C, et al. Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update. Int J Cancer. 2014;134(11):2513-2522. [CrossRef]
  • 12. Kaur H, Choi H, You YN, et al. MR imaging for preoperative evaluation of primary rectal cancer: practical considerations. RadioGraphics. 2012;32(2):389-409. [CrossRef]
  • 13. Taylor FG, Quirke P, Heald RJ, et al. Preoperative magnetic resonance imaging assessment of circumferential resection margin predicts disease-free survival and local recurrence: 5-year follow-up results of the mercury study. J Clin Oncol. 2014;32(1):34-43. [CrossRef]
  • 14. Yimei J, Ren Z, Lu X, Huan Z. A comparison between the reference values of MRI and EUS and their usefulness to surgeons in rectal cancer. Eur Rev Med Pharmacol Sci. 2012;16(15):2069-2077.
  • 15. Beets-Tan RGH, Lambregts DMJ, Maas M, et al. Magnetic resonance imaging for clinical management of rectal cancer: updated recommendations from the 2016 European Society of Gastrointestinal and Abdominal Radiology (ESGAR) consensus meeting. Eur Radiol. 2018;28(4):1465-1475. [CrossRef]
  • 16. Bipat S, Glas AS, Slors FJ, Zwinderman AH, Bossuyt PM, Stoker J. Rectal cancer: local staging and assessment of lymph node involvement with endoluminal US, CT, and MR imaging--a metaanalysis. Radiology. 2004;232(3):773-783. [CrossRef]
  • 17. You YN, Hardiman KM, Bafford A, et al. Society of Colon and Rectal Surgeons. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Rectal Cancer. Dis Colon Rectum. 2020;63(9):1191-1222.
  • 18. Dijkhoff RAP, Beets-Tan RGH, Lambregts DMJ, Beets GL, Maas M. Value of DCE-MRI for staging and response evaluation in rectal cancer: a systematic review. Eur J Radiol. 2017;95:155-168. [CrossRef]
  • 19. Al-Sukhni E, Milot L, Fruitman M, et al. Diagnostic accuracy of MRI for assessment of T category, lymph node metastases, and circumferential resection margin involvement in patients with rectal cancer: a systematic review and meta-analysis. Ann Surg Oncol. 2012;19(7):2212-2223. [CrossRef]
  • 20. Lahaye MJ, Engelen SM, Nelemans PJ, et al. Imaging for predicting the risk factors--the circumferential resection margin and nodal disease--of local recurrence in rectal cancer: a meta-analysis. Semin Ultrasound CT MR. 2005;26(4):259-268. [CrossRef]
  • 21. Matsuoka H, Nakamura A, Sugiyama M, Hachiya J, Atomi Y, Masaki T. MRI diagnosis of mesorectal lymph node metastasis in patients with rectal carcinoma. What is the optimal criterion? Anticancer Res. 2004;24(6):4097-4101.
  • 22. Brown G, Radcliffe AG, Newcombe RG, Dallimore NS, Bourne MW, Williams GT. Preoperative assessment of prognostic factors in rectal cancer using high-resolution magnetic resonance imaging. Br J Surg. 2003;90(3):355-364. [CrossRef]
  • 23. Kim JH, Beets GL, Kim MJ, Kessels AG, Beets-Tan RG. Highresolution MR imaging for nodal staging in rectal cancer: are there any criteria in addition to the size? Eur J Radiol. 2004;52(1):78-83. [CrossRef]
  • 24. Kennedy ED, Milot L, Fruitman M, et al. Development and implementation of a synoptic MRI report for preoperative staging of rectal cancer on a population-based level. Dis Colon Rectum. 2014;57(6): 700-708. [CrossRef]
  • 25. KSAR Study Group for Rectal Cancer. Essential items for structured reporting of rectal cancer MRI: 2016 consensus recommendation from the Korean Society of Abdominal Radiology. Korean J Radiol. 2017;18(1):132-151. [CrossRef]
  • 26. Beets-Tan RG, Lambregts DM, Maas M, et al. Magnetic resonance imaging for the clinical management of rectal cancer patients: recommendations from the 2012 European Society of Gastrointestinal and Abdominal Radiology (ESGAR) consensus meeting. Eur Radiol. 2013;23(9):2522-2531. [CrossRef]
  • 27. Kennedy E, Vella ET, Blair Macdonald D, Wong CS, McLeod R, Cancer Care Ontario Preoperative Assessment for Rectal Cancer Guideline Development Group. Optimisation of preoperative assessment in patients diagnosed with rectal cancer. Clin Oncol (R Coll Radiol). 2015;27(4):225-245. [CrossRef]
  • 28. Taylor F, Mangat N, Swift IR, Brown G. Proforma-based reporting in rectal cancer. Cancer Imaging. 2010;10(Spec no A):S142-S150. [CrossRef]
  • 29. Sohn B, Lim JS, Kim H, et al. MRI-detected extramural vascular invasion is an independent prognostic factor for synchronous metastasis in patients with rectal cancer. Eur Radiol. 2015;25(5):1347- 1355. [CrossRef]
  • 30. Chand M, Siddiqui MR, Swift I, Brown G. Systematic review of prognostic importance of extramural venous invasion in rectal cancer. World J Gastroenterol. 2016;22(4):1721-1726. [CrossRef]
  • 31. Rosenberg R, Maak M, Schuster T, Becker K, Friess H, Gertler R. Does a rectal cancer of the upper third behave more like a colon or a rectal cancer? Dis Colon Rectum. 2010;53(5):761-770. [CrossRef]
  • 32. Salerno G, Sinnatamby C, Branagan G, Daniels IR, Heald RJ, Moran BJ. Defining the rectum: surgically, radiologically and anatomically. Colorectal Dis. 2006;8(suppl 3):5-9. [CrossRef]
  • 33. Massalou D, Moszkowicz D, Mariage D, Baqué P, Camuzard O, Bronsard N. Is it possible to give a single definition of the rectosigmoid junction? Surg Radiol Anat. 2018;40(4):431-438. [CrossRef]
  • 34. Bagla N, Schofield JB. Rectosigmoid tumours: should we continue sitting on the fence? Colorectal Dis. 2007;9(7):606-608. [CrossRef]
  • 35. Glynne-Jones R, Wyrwicz L, Tiret E, et al. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv22-iv40. [CrossRef]
  • 36. van de Velde CJ, Boelens PG, Borras JM, et al. EURECCA colorectal: multidisciplinary management: European consensus conference colon & rectum. Eur J Cancer. 2014;50(1):1.e-e34. [CrossRef]
  • 37. González-Flores E, Losa F, Pericay C, et al. SEOM Clinical Guideline of localized rectal cancer (2016). Clin Transl Oncol. 2016;18(12):1163-1171. [CrossRef]
  • 38. Al BB, Alan PV, Mahmoud MA-H, et al. Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in oncology. J Natl Compr Canc Netw; 2018;16:874-901.
  • 39. Van Cutsem E, Dicato M, Haustermans K, et al. The diagnosis and management of rectal cancer: expert discussion and recommendations derived from the 9th World Congress on Gastrointestinal Cancer, Barcelona, 2007. Ann Oncol. 2008;19(suppl 6):vi1-vi8. [CrossRef]
  • 40. Loffeld RJLF, Flens M, Fransen G, den Boer FC, van Bochove A. The localisation of cancer in the sigmoid, rectum or rectosigmoid junction using endoscopy or radiology-what is the most accurate method? J Gastrointest Oncol. 2014;5(6):469-473. [CrossRef]
  • 41. Gopalswamy N, Shenoy VN, Choudhry U, et al. Is in vivo measurement of size of polyps during colonoscopy accurate? Gastrointest Endosc. 1997;46(6):497-502. [CrossRef]
  • 42. ASGE Standards of Practice Committee, Fisher DA, Shergill AK, et al. Role of endoscopy in the staging and management of colorectal cancer. Gastrointest Endosc. 2013;78(1):8-12. [CrossRef]
  • 43. Cranley JP, Petras RE, Carey WD, Paradis K, Sivak MV. When is endoscopic polypectomy adequate therapy for colonic polyps containing invasive carcinoma? Gastroenterology. 1986;91(2):419- 427. [CrossRef]
  • 44. Nascimbeni R, Burgart LJ, Nivatvongs S, Larson DR. Risk of lymph node metastasis in T1 carcinoma of the colon and rectum. Dis Colon Rectum. 2002;45(2):200-206. [CrossRef]
  • 45. Muller S, Chesner IM, Egan MJ, et al. Significance of venous and lymphatic invasion in malignant polyps of the colon and rectum. Gut. 1989;30(10):1385-1391. [CrossRef]
  • 46. Kantsevoy SV, Adler DG, Conway JD, et al. Endoscopic mucosal resection and endoscopic submucosal dissection. Gastrointest Endosc. 2008;68(1):11-18. [CrossRef]
  • 47. Matsuda T, Gotoda T, Saito Y, Nakajima T, Conio M. Our perspective on endoscopic resection for colorectal neoplas ms. Gastroenterol Clin Biol. 2010;34(6-7):367-370. [CrossRef]
  • 48. Fujimori T, Kawamata H, Kashida H. Precancerous lesions of the colorectum. J Gastroenterol. 2001;36(9):587-594. [CrossRef]
  • 49. Lieberman DA, Rex DK, Winawer SJ, Giardiello FM, Johnson DA, Levin TR. Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2012;143(3):844- 857. [CrossRef]
  • 50. Winawer SJ, Zauber AG, Fletcher RH, et al. Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society. Gastroenterology. 2006;130(6):1872-1885. [CrossRef]
  • 51. Bond JH. Polyp guideline: diagnosis, treatment, and surveillance for patients with colorectal polyps. Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol. 2000;95(11):3053-3063. [CrossRef]
  • 52. Kyzer S, Bégin LR, Gordon PH, Mitmaker B. The care of patients with colorectal polyps that contain invasive adenocarcinoma. Endoscopic polypectomy or colectomy? Cancer. 1992;70(8):2044- 2050. [CrossRef]
  • 53. Minamoto T, Mai M, Ogino T, et al. Early invasive colorectal carcinomas metastatic to the lymph node with attention to their nonpolypoid development. Am J Gastroenterol. 1993;88(7):1035-1039.
  • 54. Matsuda T, Saito Y, Fujii T, et al. Size does not determine the grade of malignancy of early invasive colorectal cancer. World J Gastroenterol. 2009;15(22):2708-2713. [CrossRef]
  • 55. São Julião GP, Celentano JP, Alexandre FA, Vailati BB. Local excision and endoscopic resections for early rectal cancer. Clin Colon Rect Surg. 2017;30(5):313-323. [CrossRef]
  • 56. Bach SP, Hill J, Monson JR, et al. A predictive model for local recurrence after transanal endoscopic microsurgery for rectal cancer. Br J Surg. 2009;96(3):280-290. [CrossRef]
  • 57. Lam AK, Chan SS, Leung M. Synchronous colorectal cancer: clinical, pathological and molecular implications. World J Gastroenterol. 2014;20(22):6815-6820. [CrossRef]
  • 58. Agnew JL, Abbadessa B, Leitman IM. Strategies to evaluate synchronous carcinomas of the colon and rectum in patients that present for emergent surgery. Int J Surg Oncol. 2013;2013:309439-. [CrossRef]
  • 59. Benson AB, 3rd, Venook AP, Al-Hawary MM, et al. Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018;16(7):874-901. [CrossRef]
  • 60. Nerad E, Lahaye MJ, Maas M, et al. Diagnostic accuracy of CT for local staging of colon cancer: a systematic review and meta-analysis. AJR Am J Roentgenol. 2016;207(5):984-995. [CrossRef]
  • 61. Morrin MM, Farrell RJ, Raptopoulos V, McGee JB, Bleday R, Kruskal JB. Role of virtual computed tomographic colonography in patients with colorectal cancers and obstructing colorectal lesions. Dis Colon Rectum. 2000;43(3):303-311. [CrossRef]
  • 62. Pickhardt PJ, Hassan C, Halligan S, Marmo R. Colorectal cancer: CT colonography and colonoscopy for detec tion- -syst emati c review and meta-analysis. Radiology. 2011;259(2):393-405. [CrossRef]
  • 63. Soyer P, Hamzi L, Sirol M, et al. Colon cancer: comprehensive evaluation with 64-section CT colonography using water enema as intraluminal contrast agent-a pictorial review. Clin Imaging. 2012;36(2):113-125. [CrossRef]
  • 64. Kim DH, Pickhardt PJ, Taylor AJ, et al. CT colonography versus colonoscopy for the detection of advanced Neoplasia. N Engl J Med. 2007;357(14):1403-1412. [CrossRef]
  • 65. Michielsen K, Vergote I, Op de Beeck K, et al. Whole-body MRI with diffusion-weighted sequence for staging of patients with suspected ovarian cancer: a clinical feasibility study in comparison to CT and FDG-PET/CT. Eur Radiol. 2014;24(4):889-901. [CrossRef]
  • 66. Koh JL, Yan TD, Glenn D, Morris DL. Evaluation of preoperative computed tomography in estimating peritoneal cancer index in colorectal peritoneal carcinomatosis. Ann Surg Oncol. 2009;16(2):327- 333. [CrossRef]
  • 67. Low RN, Gurney J. Diffusion-weighted MRI (DWI) in the oncology patient: value of breathhold DWI compared to unenhanced and gadolinium-enhanced MRI. J Magn Reson Imaging. 2007;25(4):848- 858. [CrossRef]
  • 68. Low RN, Barone RM, Lacey C, Sigeti JS, Alzate GD, Sebrechts CP. Peritoneal tumor: MR imaging with dilute oral barium and intravenous gadol inium -cont ainin g contrast agents compared with unenhanced MR imaging and CT. Radiology. 1997;204(2):513-520. [CrossRef]
  • 69. Low RN, Barone RM, Lucero J. Comparison of MRI and CT for predicting the Peritoneal Cancer Index (PCI) preoperatively in patients being considered for cytoreductive surgical procedures. Ann Surg Oncol. 2015;22(5):1708-1715. [CrossRef]
  • 70. Low RN, Sebrechts CP, Barone RM, Muller W. Diffusion-weighted MRI of peritoneal tumors: comparison with conventional MRI and surgical and histopathologic findings--a feasibility study. AJR Am J Roentgenol. 2009;193(2):461-470. [CrossRef]
  • 71. Low RN. Preoperative and surveillance MR imaging of patients undergoing cytoreductive surgery and heated intraperitoneal chemotherapy. J Gastrointest Oncol. 2016;7(1):58-71. [CrossRef]
  • 72. Heald RJ, Ryall R. Recurrent cancer after restorative resection of the rectum. Br Med J (Clin Res Ed). 1982;284(6318):826-827. [CrossRef]
  • 73. Martling AL, Holm T, Rutqvist LE, Moran BJ, Heald RJ, Cedemark B. Effect of a surgical training programme on outcome of rectal cancer in the County of Stockholm. Stockholm Colorectal Cancer Study Group, Basingstoke Bowel Cancer Research Project. Lancet. 2000;356(9224):93-96. [CrossRef]
  • 74. Quirke P, Steele R, Monson J, et al. Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trial. Lancet. 2009;373(9666):821-828. [CrossRef]
  • 75. Nagtegaal ID, Marijnen CA, Kranenbarg EK, et al. Circumferential margin involvement is still an important predictor of local recurrence in rectal carcinoma: not one millimeter but two millimeters is the limit. Am J Surg Pathol. 2002;26(3):350-357. [CrossRef]
  • 76. Kapiteijn E, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001;345(9):638-646. [CrossRef]
  • 77. Peeters KC, Marijnen CA, Nagtegaal ID, et al. The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg. 2007;246(5):693-701. [CrossRef]
  • 78. van Gijn W, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol. 2011;12(6):575-582. [CrossRef]
  • 79. Sauer R, Liersch T, Merkel S, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012;30(16):1926- 1933. [CrossRef]
  • 80. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351(17):1731-1740. [CrossRef]
  • 81. Bosset JF, Collette L, Calais G, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355(11):1114- 1123. [CrossRef]
  • 82. Sebag-Montefiore D, Stephens RJ, Steele R, et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet. 2009;373(9666):811-820. [CrossRef]
  • 83. Monson JR, Weiser MR, Buie WD, et al. Practice parameters for the management of rectal cancer (revised). Dis Colon Rectum. 2013;56(5):535-550. [CrossRef]
  • 84. Lopez-Kostner F, Lavery IC, Hool GR, Rybicki LA, Fazio VW. Total mesorectal excision is not necessary for cancers of the upper rectum. Surgery. 1998;124(4):612-618. [CrossRef]
  • 85. Scott N, Jackson P, al-Jaberi T, Dixon MF, Quirke P, Finan PJ. Total mesorectal excision and local recurrence: a study of tumour spread in the mesorectum distal to rectal cancer. Br J Surg. 1995;82(8): 1031-1033. [CrossRef]
  • 86. Hida J, Yasutomi M, Maruyama T, Fujimoto K, Uchida T, Okuno K. Lymph node metastases detected in the mesorectum distal to carcinoma of the rectum by the clearing method: justification of total mesorectal excision. J Am Coll Surg. 1997;184(6):584-588.
  • 87. Law WL, Chu KW. Anterior resection for rectal cancer with mesorectal excision: a prospective evaluation of 622 patients. Ann Surg. 2004;240(2):260-268. [CrossRef]
  • 88. Karanjia ND, Corder AP, Bearn P, Heald RJ. Leakage from stapled low anastomosis after total mesorectal excision for carcinoma of the rectum. Br J Surg. 1994;81(8):1224-1226. [CrossRef]
  • 89. Matthiessen P, Hallböök O, Rutegård J, Simert G, Sjödahl R. Defunctioning stoma reduces symptomatic anastomotic leakage after low anterior resection of the rectum for cancer: a randomized multicenter trial. Ann Surg. 2007;246(2):207-214. [CrossRef]
  • 90. Veenhof AA, van der Peet DL, Meijerink WJ, Cuesta MA. Defunctioning stoma reduces symptomatic anastomotic leakage after low anterior resection of the rectum for cancer: a randomized multicenter trial. Ann Surg. 2008;247(4):718-719. [CrossRef]
  • 91. Quirke P, Dixon MF, Durdey P, Williams NS. Local recurrence of rectal adenocarcinoma due to inadequate surgical resection: histopathological study of lateral tumour spread and surgical excision. Lancet. 1986;328:996-999.
  • 92. Keranmu A, Liu HN, Wu YC, et al. A negative-doughnut distal resection margin less than 5 mm does not affect prognosis in rectal cancer. J Surg Oncol. 2018;118(3):536-543. [CrossRef]
  • 93. Fitzgerald TL, Brinkley J, Zervos EE. Pushing the envelope beyond a centimeter in rectal cancer: oncologic implications of close, but negative margins. J Am Coll Surg. 2011;213(5):589-595. [CrossRef]
  • 94. Rullier E, Denost Q, Vendrely V, Rullier A, Laurent C. Low rectal cancer: classification and standardization of surgery. Dis Colon Rectum. 2013;56(5):560-567. [CrossRef]
  • 95. West NP, Finan PJ, Anderin C, Lindholm J, Holm T, Quirke P. Evidence of the oncologic superiority of cylindrical abdominoperineal excision for low rectal cancer. J Clin Oncol. 2008;26(21):3517-3522. [CrossRef]
  • 96. Palmer G, Anderin C, Martling A, Holm T. Local control and survival after extralevator abdominoperineal excision for locally advanced or low rectal cancer. Colorectal Dis. 2014;16(7):527-532. [CrossRef]
  • 97. Morson C. The Hampstead general: beginning and ending. Br Med J. 1964;2(5417):1126-1127. [CrossRef]
  • 98. Jayne D, Pigazzi A, Marshall H, et al. Effect of robotic-assisted vs conventional laparoscopic surgery on risk of conversion to open laparotomy among patients undergoing resection for rectal cancer: the ROLARR randomized clinical trial. JAMA. 2017;318(16):1569- 1580. [CrossRef]
  • 99. Bonjer HJ, Deijen CL, Abis GA, et al. A randomized trial of laparoscopic versus open surgery for rectal cancer. N Engl J Med. 2015;372(14):1324-1332. [CrossRef]
  • 100. Jeong SY, Park JW, Nam BH, et al. Open versus laparoscopic surgery for mid-rectal or low-rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): survival outcomes of an openlabel, non-inferiority, randomised controlled trial. Lancet Oncol. 2014;15(7):767-774. [CrossRef]
  • 101. Green BL, Marshall HC, Collinson F, et al. Long-term follow-up of the Medical Research Council CLASICC trial of conventional versus laparoscopically assisted resection in colorectal cancer. Br J Surg. 2013;100(1):75-82. [CrossRef]
  • 102. Merkel S, Mansmann U, Siassi M, Papadopoulos T, Hohenberger W, Hermanek P. The prognostic inhomogeneity in pT3 rectal carcinomas. Int J Colorectal Dis. 2001;16(5):298-304. [CrossRef]
  • 103. Stornes T, Wibe A, Nesbakken A, Myklebust TÅ, Endreseth BH. National early rectal cancer treatment revisited. Dis Colon Rectum. 2016;59(7):623-629. [CrossRef]
  • 104. Shinto E, Hida JI, Kobayashi H, et al. Prominent information of jN3 positive in Stage III colorectal cancer removed by D3 dissection: retrospective analysis of 6866 patients from a multi-institutional database in Japan. Dis Colon Rectum. 2018;61(4):447-453. [CrossRef]
  • 105. Kim TH, Jeong SY, Choi DH, et al. Lateral lymph node metastasis is a major cause of locoregional recurrence in rectal cancer treated with preoperative chemoradiotherapy and curative resection. Ann Surg Oncol. 2008;15(3):729-737. [CrossRef]
  • 106. Kusters M, Uehara K, Velde CJHV, Moriya Y. Is there any reason to still consider lateral lymph node dissection in rectal cancer? Rationale and technique. Clin Colon Rect Surg. 2017;30(5):346-356. [CrossRef]
  • 107. Ogura A, Konishi T, Cunningham C, et al. Neoadjuvant (Chemo) radiotherapy with total mesorectal excision only is not sufficient to prevent lateral local recurrence in enlarged nodes: results of the multicenter lateral node study of patients With low cT3/4 rectal cancer. J Clin Oncol. 2019;37(1):33-43. [CrossRef]
  • 108. Kusters M, Beets GL, van de Velde CJ, et al. A comparison between the treatment of low rectal cancer in Japan and the Netherlands, focusing on the patterns of local recurrence. Ann Surg. 2009;249(2):229-235. [CrossRef]
  • 109. Wei M, Wu Q, Fan C, et al. Lateral pelvic lymph node dissection after neoadjuvant chemo-radiation for preoperative enlarged lateral nodes in advanced low rectal cancer: study protocol for a randomized controlled trial. Trials. 2016;17(1):561-. [CrossRef]
  • 110. Cirocchi R, Farinella E, Trastulli S, et al. Safety and efficacy of endoscopic colonic stenting as a bridge to surgery in the management of intestinal obstruction due to left colon and rectal cancer: a systematic review and meta-analysis. Surg Oncol. 2013;22(1):14-21. [CrossRef]
  • 111. Súarez J, Jiménez J, Vera R, et al. Stent or surgery for incurable obstructive colorectal cancer: an individualized decision. Int J Colorectal Dis. 2010;25(1):91-96. [CrossRef]
  • 112. van Hooft JE, van Halsema EE, Vanbiervliet G, et al. Selfexpandable metal stents for obstructing colonic and extracolonic cancer: European Society of Gastrointestinal Endoscopy (ESGE) clinical guideline. Endoscopy. 2014;46(11):990-1053. [CrossRef]
  • 113. Choi Y, Choi HS, Jeon WK, et al. Optimal number of endoscopic biopsies in diagnosis of advanced gastric and colorectal cancer. J Korean Med Sci. 2012;27(1):36-39. [CrossRef]
  • 114. Colleypriest BJ, Marden PF, Linehan JD. What is the optimal number of biopsies to diagnose a tumor found during colonoscopy? J Clin Gastroenterol. 2009;43(10):1012-1013. [CrossRef]
  • 115. Vilkin A, Leibovici-Weissman Y, Halpern M, et al. Immunohistochemistry staining for mismatch repair proteins: the endoscopic biopsy material provides useful and coherent results. Hum Pathol. 2015;46(11):1705-1711. [CrossRef]
  • 116. O’Brien O, Ryan É, Creavin B, et al. Correlation of immunohistochemical mismatch repair protein status between colorectal carcinoma endoscopic biopsy and resection specimens. J Clin Pathol. 2018;71(7):631-636. [CrossRef]
  • 117. Vilkin A, Halpern M, Morgenstern S, et al. How reliable is immunohistochemical staining for DNA mismatch repair proteins performed after neoadjuvant chemoradiation? Hum Pathol. 2014;45(10):2029-2036. [CrossRef]
  • 118. Ryan ÉJ, Creavin B, Khaw YL, et al. Effects of CDX2 on prognosis and chemotherapy responsiveness in mismatch repair-deficient colorectal cancer. BJS Open. 2018;2(6):456-463. [CrossRef]
  • 119. Dalerba P, Sahoo D, Paik S, et al. CDX2 as a prognostic biomarker in Stage II and Stage III colon cancer. N Engl J Med. 2016;374(3):211- 222. [CrossRef]
  • 120. Kikuchi R, Takano M, Takagi K, et al. Management of early invasive colorectal cancer. Risk of recurrence and clinical guidelines. Dis Colon Rectum. 1995;38(12):1286-1295. [CrossRef]
  • 121. Haggitt RC, Glotzbach RE, Soffer EE, Wruble LD. Prognostic factors in colorectal carcinomas arising in adenomas: implications for lesions removed by endoscopic polypectomy. Gastroenterology. 1985;89(2):328-336. [CrossRef]
  • 122. Merkel S, Weber K, Schellerer V, et al. Prognostic subdivision of ypT3 rectal tumours according to extension beyond the muscularis propria. Br J Surg. 2014;101(5):566-572. [CrossRef]
  • 123. Miyoshi M, Ueno H, Hashiguchi Y, Mochizuki H, Talbot IC. Extent of mesorectal tumor invasion as a prognostic factor after curative surgery for T3 rectal cancer patients. Ann Surg. 2006;243(4):492- 498. [CrossRef]
  • 124. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359(17):1757-1765. [CrossRef]
  • 125. Bardelli A, Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol. 2010;28(7):1254-1261. [CrossRef]
  • 126. Sorich MJ, Wiese MD, Rowland A, Kichenadasse G, McKinnon RA, Karapetis CS. Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. Ann Oncol. 2015;26(1):13-21. [CrossRef]
  • 127. Sepulveda AR, Hamilton SR, Allegra CJ, et al. Molecular biomarkers for the evaluation of colorectal cancer: guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology. J Clin Oncol. 2017;35(13):1453-1486. [CrossRef]
  • 128. Marginean EC, Melosky B. Is there a role for programmed death Ligand-1 testing and immunotherapy in colorectal cancer with microsatellite instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications. Arch Pathol Lab Med. 2018;142(1):17-25. [CrossRef]
  • 129. van Lier MG, Wagner A, van Leerdam ME, et al. A review on the molecular diagnostics of Lynch syndrome: a central role for the pathology laboratory. J Cell Mol Med. 2010;14(1-2):181-197. [CrossRef]
  • 130. Markow M, Chen W, Frankel WL. Immunohistochemical pitfalls: common mistakes in the evaluation of Lynch syndrome. Surg Pathol Clin. 2017;10(4):977-1007. [CrossRef]
  • 131. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487(7407):330-337. [CrossRef]
  • 132. Guinney J, Dienstmann R, Wang X, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21(11):1350-1356. [CrossRef]
  • 133. Müller MF, Ibrahim AE, Arends MJ. Molecular pathological classification of colorectal cancer. Virchows Arch. 2016;469(2):125-134. [CrossRef]
  • 134. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for Rectal Cancer. N Engl J Med. 2004;351(17):1731-1740. [CrossRef]
  • 135. Kapiteijn E, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001;345(9):638-646. [CrossRef]
  • 136. Ngan SY, Burmeister B, Fisher RJ, et al. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. J Clin Oncol. 2012;30(31):3827-3833. [CrossRef]
  • 137. Braendengen M, Tveit KM, Berglund A, et al. Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer. J Clin Oncol. 2008;26(22): 3687-3694. [CrossRef]
  • 138. Bujko K, Partycki M, Pietrzak L. Neoadjuvant radiotherapy (5 x 5 Gy): immediate versus delayed surgery. Recent Results Cancer Res. 2014;203:171-187. [CrossRef]
  • 139. Erlandsson J, Holm T, Pettersson D, et al. Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial. Lancet Oncol. 2017;18(3):336-346. [CrossRef]
  • 140. Willett CG, Badizadegan K, Ancukiewicz M, Shellito PC. Prognostic factors in stage T3N0 rectal cancer: do all patients require postoperative pelvic irradiation and chemotherapy? Dis Colon Rectum. 1999;42(2):167-173. [CrossRef]
  • 141. Guillem JG, Díaz-González JA, Minsky BD, et al. cT3N0 rectal cancer: potential overtreatment with preoperative chemoradiotherapy is warranted. J Clin Oncol. 2008;26(3):368-373. [CrossRef]
  • 142. Brown G, Richards CJ, Bourne MW, et al. Morphologic predictors of lymph node status in rectal cancer with use of high- spati al-re solut ion MR imaging with histopathologic comparison. Radiology. 2003;227(2):371-377. [CrossRef]
  • 143. Smalley SR, Benedetti JK, Williamson SK, et al. Phase III trial of fluorouracil-based chemotherapy regimens plus radiotherapy in postoperative adjuvant rectal cancer: GI INT 0144. J Clin Oncol. 2006;24(22):3542-3547. [CrossRef]
  • 144. Hofheinz RD, Wenz F, Post S, et al. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol. 2012;13(6):579-588. [CrossRef]
  • 145. Allegra CJ, Yothers G, O’Connell MJ, et al. Neoadjuvant 5-FU or capecitabine plus radiation with or without oxaliplatin in rectal cancer patients: a phase III randomized clinical trial. J Natl Cancer Inst. 2015;107(11). [CrossRef]
  • 146. Aschele C, Cionini L, Lonardi S, et al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol. 2011;29(20):2773-2780. [CrossRef]
  • 147. Gérard JP, Azria D, Gourgou-Bourgade S, et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial Accord 12/0405-Prodige 2. J Clin Oncol. 2010;28(10):1638-1644. [CrossRef]
  • 148. Gérard JP, Azria D, Gourgou-Bourgade S, et al. Clinical outcome of the Accord 12/0405 PRODIGE 2 randomized trial in rectal cancer. J Clin Oncol. 2012;30(36):4558-4565. [CrossRef]
  • 149. Schmoll H-J, Haustermans K, Price TJ, et al. Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine +/− oxaliplatin in locally advanced rectal cancer: final results of PETACC-6. J Clin Oncol. 2018;36(15_suppl):3500-. [CrossRef]
  • 150. Deng Y, Chi P, Lan P, et al. Modified FOLFOX6 with or without radiation versus fluorouracil and leucovorin with radiation in neoadjuvant treatment of locally advanced rectal cancer: initial results of the Chinese FOWARC multicenter, open-label, randomized three-arm Phase III trial. J Clin Oncol. 2016;34(27):3300-3307. [CrossRef]
  • 151. Rödel C, Liersch T, Becker H, et al. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol. 2012;13(7):679-687. [CrossRef]
  • 152. Methy N, Bedenne L, Conroy T, et al. Surrogate end points for overall survival and local control in neoadjuvant rectal cancer trials: statistical evaluation based on the FFCD 9203 trial. Ann Oncol. 2010;21(3):518-524. [CrossRef]
  • 153. Kalady MF, de Campos-Lobato LF, Stocchi L, et al. Predictive factors of pathologic complete response after neoadjuvant chemoradiation for rectal cancer. Ann Surg. 2009;250(4):582-589. [CrossRef]
  • 154. Wolthuis AM, Penninckx F, Haustermans K, et al. Impact of interval between neoadjuvant chemoradiotherapy and TME for locally advanced rectal cancer on pathologic response and oncologic outcome. Ann Surg Oncol. 2012;19(9):2833-2841. [CrossRef]
  • 155. Lefevre JH, Mineur L, Kotti S, et al. Effect of Interval (7 or 11 weeks) between neoadjuvant radiochemotherapy and Surgery on Complete Pathologic Response in Rectal Cancer: a multicenter, randomized, controlled trial (GRECCAR-6). J Clin Oncol. 2016;34(31): 3773-3780. [CrossRef]
  • 156. Habr-Gama A, Perez RO, Proscurshim I, et al. Interval between surgery and neoadjuvant chemoradiation therapy for distal rectal cancer: does delayed surgery have an impact on outcome? Int J Radiat Oncol Biol Phys. 2008;71(4):1181-1188. [CrossRef]
  • 157. Habr-Gama A, Perez RO, Nadalin W, et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg. 2004;240(4):711- 718. [CrossRef]
  • 158. Habr-Gama A, Perez RO, Sabbaga J, Nadalin W, São Julião GP, Gama-Rodrigues J. Increasing the rates of complete response to neoadjuvant chemoradiotherapy for distal rectal cancer: results of a prospective study using additional chemotherapy during the resting period. Dis Colon Rectum. 2009;52(12):1927-1934. [CrossRef]
  • 159. Gao YH, Zhang X, An X, et al. Oxaliplatin and capecitabine concomitant with neoadjuvant radiotherapy and extended to the resting period in high risk locally advanced rectal cancer. Strahlenther Onkol. 2014;190(2):158-164. [CrossRef]
  • 160. Gao YH, Lin JZ, An X, et al. Neoadjuvant sandwich treatment with oxaliplatin and capecitabine administered prior to, concurrently with, and following radiation therapy in locally advanced rectal cancer: a prospective phase 2 trial. Int J Radiat Oncol Biol Phys. 2014;90(5):1153-1160. [CrossRef]
  • 161. Zhu J, Gu W, Lian P, et al. A phase II trial of neoadjuvant IMRTbased chemoradiotherapy followed by one cycle of capecitabine for stage II/III rectal adenocarcinoma. Radiat Oncol. 2013;8:130-. [CrossRef]
  • 162. Zampino MG, Magni E, Leonardi MC, et al. Capecitabine initially concomitant to radiotherapy then perioperatively administered in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2009;75(2):421-427. [CrossRef]
  • 163. Garcia-Aguilar J, Chow OS, Smith DD, et al. Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. Lancet Oncol. 2015;16(8): 957-966. [CrossRef]
  • 164. Habr-Gama A, Sabbaga J, Gama-Rodrigues J, et al. Watch and wait approach following extended neoadjuvant chemoradiation for distal rectal cancer: are we getting closer to anal cancer management? Dis Colon Rectum. 2013;56(10):1109-1117. [CrossRef]
  • 165. Habr-Gama A, Perez RO, São Julião GP, et al. Consolidation chemotherapy during neoadjuvant chemoradiation (CRT) for distal rectal cancer leads to sustained decrease in tumor metabolism when compared to standard CRT regimen. Radiat Oncol. 2016;11:24. [CrossRef]
  • 166. Hiotis SP, Weber SM, Cohen AM, et al. Assessing the predictive value of clinical complete response to neoadjuvant therapy for rectal cancer: an analysis of 488 patients. J Am Coll Surg. 2002;194(2):131- 135. [CrossRef]
  • 167. Stipa F, Zernecke A, Moore HG, et al. Residual mesorectal lymph node involvement following neoadjuvant combined-modality therapy: rationale for radical resection? Ann Surg Oncol. 2004;11(2):187-191. [CrossRef]
  • 168. Habr-Gama A, Perez RO, Nadalin W, et al. Long-term results of preoperative chemoradiation for distal rectal cancer correlation between final stage and survival. J Gastrointest Surg. 2005;9(1):90- 101. [CrossRef]
  • 169. Kristiansen C, Loft A, Berthelsen AK, et al. PET/CT and histopathologic response to preoperative chemoradiation therapy in locally advanced rectal cancer. Dis Colon Rectum. 2008;51(1):21-25. [CrossRef]
  • 170. Douglass HO, Jr, Moertel CG, Mayer RJ, et al. Survival after postoperative combination treatment of rectal cancer. N Engl J Med. 1986;315(20):1294-1295. [CrossRef]
  • 171. Fisher B, Wolmark N, Rockette H, et al. Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01. J Natl Cancer Inst. 1988;80(1):21-29. [CrossRef]
  • 172. Krook JE, Moertel CG, Gunderson LL, et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med. 1991;324(11):709-715. [CrossRef]
  • 173. Petersen SH, Harling H, Kirkeby LT, Wille-Jørgensen P, Mocellin S. Postoperative adjuvant chemotherapy in rectal cancer operated for cure. Cochrane Database Syst Rev. 2012;(3):CD004078. [CrossRef]
  • 174. Bosset JF, Calais G, Mineur L, et al. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. Lancet Oncol. 2014;15(2):184-190. [CrossRef]
  • 175. Sainato A, Cernusco Luna Nunzia V, Valentini V, et al. No benefit of adjuvant Fluorouracil Leucovorin chemotherapy after neoadjuvant chemoradiotherapy in locally advanced cancer of the rectum (LARC): long term results of a randomized trial (I-CNR-RT). Radiother Oncol. 2014;113(2):223-229. [CrossRef]
  • 176. Breugom AJ, van Gijn W, Muller EW, et al. Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo) radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial. Ann Oncol. 2015;26(4):696-701. [CrossRef]
  • 177. Glynne-Jones R, Counsell N, Quirke P, et al. Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control. Ann Oncol. 2014;25(7):1356-1362. [CrossRef]
  • 178. Breugom AJ, Swets M, Bosset JF, et al. Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data. Lancet Oncol. 2015;16(2):200-207. [CrossRef]
  • 179. Hong YS, Kim SY, Lee JS, et al. Long-term results of the ADORE trial: adjuvant oxaliplatin, leucovorin, and 5-fluorouracil (FOLFOX) versus 5-fluorouracil and leucovorin (FL) after preoperative chemoradiotherapy and surgery for locally advanced rectal cancer. J Clin Oncol. 2018;36(15_suppl):3501-. [CrossRef]
  • 180. Dossa F, Acuna SA, Rickles AS, et al. Association Between adjuvant chemotherapy and overall survival in patients with rectal cancer and pathological complete response after neoadjuvant chemotherapy and resection. JAMA Oncol. 2018;4(7):930-937. [CrossRef]
  • 181. Polanco PM, Mokdad AA, Zhu H, Choti MA, Huerta S. Association of adjuvant chemotherapy with overall survival in patients with rectal cancer and pathologic complete response following neoadjuvant chemotherapy and resection. JAMA Oncol. 2018;4(7):938-943. [CrossRef]
  • 182. Sun Z, Adam MA, Kim J, Shenoi M, Migaly J, Mantyh CR. Optimal timing to surgery after neoadjuvant chemoradiotherapy for locally advanced rectal cancer. J Am Coll Surg. 2016;222(4):367-374. [CrossRef]
  • 183. Probst CP, Becerra AZ, Aquina CT, et al. Extended intervals after neoadjuvant therapy in locally advanced rectal cancer: the key to improved tumor response and potential organ preservation. J Am Coll Surg. 2015;221(2):430-440. [CrossRef]
  • 184. Kwak YK, Kim K, Lee JH, et al. Timely tumor response analysis after preoperative chemoradiotherapy and curative surgery in locally advanced rectal cancer: a multi-institutional study for optimal surgical timing in rectal cancer. Radiother Oncol. 2016;119(3):512- 518. [CrossRef]
  • 185. Sloothaak DA, Geijsen DE, van Leersum NJ, et al. Optimal time interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer. Br J Surg. 2013;100(7):933-939. [CrossRef]
  • 186. Du D, Su Z, Wang D, Liu W, Wei Z. Optimal interval to surgery after neoadjuvant chemoradiotherapy in rectal cancer: a systematic review and meta-analysis. Clin Colorectal Cancer. 2018;17(1):13-24. [CrossRef]
  • 187. Habr-Gama A, São Julião GP, Vailati BB, et al. Organ preservation in cT2N0 rectal cancer after neoadjuvant chemoradiation therapy: the impact of radiation therapy doseescalation and consolidation chemotherapy. Ann Surg. 2019;269(1):102-107. [CrossRef]
  • 188. Kim CW, Kang BM, Kim IY, et al. Korean Society of Coloproctology (KSCP) trial of cONsolidation Chemotherapy for locally advanced mid or low rectal cancer after neoadjuvant concurrent chemoradiotherapy: a multicenter, randomized controlled trial (KONCLUDE). BMC Cancer. 2018;18(1):538. [CrossRef]
  • 189. São Julião GP, Habr-Gama A, Vailati BB, et al. Is neoadjuvant chemoradiation with dose-escalation and consolidation chemotherapy sufficient to increase surgery-free and distant metastases-free survival in baseline cT3 rectal cancer? Eur J Surg Oncol. 2018;44(1):93-99. [CrossRef]
  • 190. Marco MR, Zhou L, Patil S, et al. Consolidation mFOLFOX6 chemotherapy after chemoradiotherapy improves survival in patients with locally advanced rectal cancer: final results of a multicenter phase II trial. Dis Colon Rectum. 2018;61(10):1146-1155. [CrossRef]
  • 191. Saklani AP, Bae SU, Clayton A, Kim NK. Magnetic resonance imaging in rectal cancer: a surgeon’s perspective. World J Gastroenterol. 2014;20(8):2030-2041. [CrossRef]
  • 192. Cunningham C, Leong K, Clark S, et al. Association of coloproctology of Great Britain & Ireland (ACPGBI): guidelines for the management of cancer of the colon, rectum and anus (2017) - diagnosis, investigations and screening. Colorectal Dis. 2017; 19(suppl 1):9-17. [CrossRef]
  • 193. Battersby NJ, How P, Moran B, et al. Prospective validation of a low rectal cancer magnetic resonance imaging staging system and development of a local recurrence risk stratification model: the MERCURY II study. Ann Surg. 2016;263(4):751-760. [CrossRef]
  • 194. Zhan S, Wang X, Huang X, Zhu H. Magnetic resonance imaging in restaging rectal cancer after neoadjuvant chemoradiotherapy. J BUON. 2015;20(1):62-67.
  • 195. van der Paardt MP, Zagers MB, Beets-Tan RG, Stoker J, Bipat S. Patients who undergo preoperative chemoradiotherapy for locally advanced rectal cancer restaged by using diagnostic MR imaging: a systematic review and meta-analysis. Radiology. 2013;269(1):101- 112. [CrossRef]
  • 196. Park HJ, Jang JK, Park SH, et al. Restaging abdominopelvic computed tomography Before surgery after preoperative chemoradiotherapy in patients with locally advanced rectal cancer. JAMA Oncol. 2018;4(2):259-262. [CrossRef]
  • 197. Figueiredo MN, Mège D, Maggiori L, Ferron M, Panis Y. When is the best time for temporary stoma closure in laparoscopic sphincter-saving surgery for rectal cancer? A study of 259 consecutive patients. Tech Coloproctol. 2015;19(8):469-474. [CrossRef]
  • 198. Danielsen AK, Park J, Jansen JE, et al. Early closure of a temporary ileostomy in patients with rectal cancer: a multicenter randomized controlled trial. Ann Surg. 2017;265(2):284-290. [CrossRef]
  • 199. Farag S, Rehman S, Sains P, Baig MK, Sajid MS. Early vs delayed closure of loop defunctioning ileostomy in patients undergoing distal colorectal resections: an integrated systematic review and metaanalysis of published randomized controlled trials. Colorectal Dis. 2017;19(12):1050-1057. [CrossRef]
  • 200. Vaughan-Shaw PG, Gash K, Adams K, et al. Protocol for a multicentre, dual prospective and retrospective cohort study investigating timing of ileostomy closure after anterior resection for rectal cancer: the CLOSurE of Ileostomy Timing (CLOSE-IT) study. BMJ, (Open). 2018;8(10):e023305. [CrossRef]
  • 201. Dossa F, Chesney TR, Acuna SA, Baxter NN. A watch-and-wait approach for locally advanced rectal cancer after a clinical complete response following neoadjuvant chemoradiation: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2017;2(7): 501-513. [CrossRef]
  • 202. Glynne-Jones R, Wallace M, Livingstone JI, Meyrick-Thomas J. Complete clinical response after preoperative chemoradiation in rectal cancer: is a “wait and see” policy justified? Dis Colon Rectum. 2008;51:10-20.
  • 203. Sammour T, Price BA, Krause KJ, Chang GJ. Nonoperative management or ‘watch and wait’ for rectal cancer with complete clinical response after neoadjuvant chemoradiotherapy: a critical appraisal. Ann Surg Oncol. 2017;24(7):1904-1915. [CrossRef]
  • 204. Kong JC, Guerra GR, Warrier SK, Ramsay RG, Heriot AG. Outcome and salvage surgery following “watch and wait” for rectal cancer after neoadjuvant therapy: a systematic review. Dis Colon Rectum. 2017;60(3):335-345. [CrossRef]
  • 205. Glynne-Jones R, Hughes R. Critical appraisal of the ‘wait and see’ approach in rectal cancer for clinical complete responders after chemoradiation. Br J Surg. 2012;99(7):897-909. [CrossRef]
  • 206. On J, Aly EH. ‘Watch and wait’ in rectal cancer: summary of the current evidence. Int J Colorectal Dis. 2018;33(9):1159-1168. [CrossRef]
  • 207. Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg. 2004;240(4):644-57; discussion 657. [CrossRef]
  • 208. Adam R. Chemotherapy and surgery: new perspectives on the treatment of unresectable liver metastases. Ann Oncol. 2003;14(suppl 2):ii13-ii16. [CrossRef]
  • 209. Folprecht G, Grothey A, Alberts S, Raab HR, Köhne CH. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol. 2005;16(8):1311-1319. [CrossRef]
  • 210. Kim JW, Kim YB, Kim NK, et al. The role of adjuvant pelvic radiotherapy in rectal cancer with synchronous liver metastasis: a retrospective study. Radiat Oncol. 2010;5:75. [CrossRef]
  • 211. Butte JM, Gonen M, Ding P, et al. Patterns of failure in patients with early onset (synchronous) resectable liver metastases from rectal cancer. Cancer. 2012;118(21):5414-5423. [CrossRef]
  • 212. Viganò L, Ferrero A, Amisano M, Russolillo N, Capussotti L. Comparison of laparoscopic and open intraoperative ultrasonography for staging liver tumours. Br J Surg. 2013;100(4):535-542. [CrossRef]
  • 213. Milsom JW, Jerby BL, Kessler H, Hale JC, Herts BR, O’Malley CM. Prospective, blinded comparison of laparoscopic ultrasonography vs. contrast-enhanced computerized tomography for liver assessment in patients undergoing colorectal carcinoma surgery. Dis Colon Rectum. 2000;43(1):44-49. [CrossRef]
  • 214. Abu Hilal M, Aldrighetti L, Dagher I, et al. The Southampton consensus guidelines for laparoscopic liver surgery: from indication to implementation. Ann Surg. 2018;268(1):11-18. [CrossRef]
  • 215. Ellebaek SB, Fristrup CW, Mortensen MB. Intraoperative ultrasound as a screening modality for the detection of liver metastases during resection of primary colorectal cancer - a systematic review. Ultrasound Int Open. 2017;3(2):E60-E68. [CrossRef]
  • 216. Watanabe T, Muro K, Ajioka Y, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. Int J Clin Oncol. 2018;23(1):1-34. [CrossRef]
  • 217. Tsilimigras DI, Ntana sis-S tatho poulo s I, Bagante F, et al. Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: a systematic review of the current evidence. Surg Oncol. 2018;27(2):280-288. [CrossRef]
  • 218. Oshi M, Margonis GA, Sawada Y, et al. Higher tumor burden neutralizes negative margin status in hepatectomy for colorectal cancer liver metastasis. Ann Surg Oncol. 2019;26(2):593-603. [CrossRef]
  • 219. Margonis GA, Buettner S, Andreatos N, et al. Association of BRAF mutations with survival and recurrence in surgically treated patients with metastatic colorectal liver cancer. JAMA Surg. 2018;153(7):e180996. [CrossRef]
  • 220. Margonis GA, Sasaki K, Andreatos N, et al. KRAS mutation status dictates optimal surgical margin width in patients undergoing resection of colorectal liver metastases. Ann Surg Oncol. 2017;24(1): 264-271. [CrossRef]
  • 221. Margonis GA, Sasaki K, Kim Y, et al. Tumor biology rather than surgical technique dictates prognosis in colorectal cancer liver metastases. J Gastrointest Surg. 2016;20(11):1821-1829. [CrossRef]
  • 222. Wang J, Margonis GA, Amini N, et al. The prognostic value of varying definitions of positive resection margin in patients with colorectal cancer liver metastases. J Gastrointest Surg. 2018;22(8): 1350-1357. [CrossRef]
  • 223. Margonis GA, Sergentanis TN, Ntana sis-S tatho poulo s I, et al. Impact of surgical margin width on recurrence and overall survival following R0 hepatic resection of colorectal metastases: a systematic review and meta-analysis. Ann Surg. 2018;267(6):1047-1055. [CrossRef]
  • 224. Postriganova N, Kazaryan AM, Røsok BI, Fretland Å, Barkhatov L, Edwin B. Margin status after laparoscopic resection of colorectal liver metastases: does a narrow resection margin have an influence on survival and local recurrence? HPB (Oxford). 2014;16(9):822-829. [CrossRef]
  • 225. Truant S, Séquier C, Leteurtre E, et al. Tumour biology of colorectal liver metastasis is a more important factor in survival than surgical margin clearance in the era of modern chemotherapy regimens. HPB (Oxford). 2015;17(2):176-184. [CrossRef]
  • 226. Eveno C, Karoui M, Gayat E, et al. Liver resection for colorectal liver metastases with peri-operative chemotherapy: oncological results of R1 resections. HPB (Oxford). 2013;15(5):359-364. [CrossRef]
  • 227. Hamady ZZ, Lodge JP, Welsh FK, et al. One-millimeter cancerfree margin is curative for colorectal liver metastases: a propensity score case-match approach. Ann Surg. 2014;259(3):543-548. [CrossRef]
  • 228. Sadot E, Groot Koerkamp B, Leal JN, et al. Resection margin and survival in 2368 patients undergoing hepatic resection for metastatic colorectal cancer: surgical technique or biologic surrogate? Ann Surg. 2015;262(3):476-485. [CrossRef]
  • 229. Margonis GA, Spolverato G, Kim Y, Ejaz A, Pawlik TM. Intraoperative surgical margin re-resection for colorectal liver metastasis: is it worth the effort? J Gastrointest Surg. 2015;19(4):699- 707. [CrossRef]
  • 230. Khan SA, Matthews JB. Intraoperative margin re-resection for colorectal cancer liver metastases. Hepatobiliary Surg Nutr. 2013;2(2):108-112. [CrossRef]
  • 231. Viganò L, Procopio F, Cimino MM, et al. Is tumor detachment from vascular structures equivalent to R0 resection in surgery for colorectal liver metastases? An observational cohort. Ann Surg Oncol. 2016;23(4):1352-1360. [CrossRef]
  • 232. Moris D, Ronnekleiv-Kelly S, Rahnemai-Azar AA, et al. Parenchymal-sparing versus anatomic liver resection for colorectal liver metastases: a systematic review. J Gastrointest Surg. 2017;21(6):1076-1085. [CrossRef]
  • 233. Tang H, Li B, Zhang H, Dong J, Lu W. Comparison of anatomical and nonanatomical hepatectomy for colorectal liver metastasis: a meta-analysis of 5207 patients. Sci Rep. 2016;6:32304-. [CrossRef]
  • 234. Sui CJ, Cao L, Li B, et al. Anatomical versus nonanatomical resection of colorectal liver metastases: a meta-analysis. Int J Colorectal Dis. 2012;27(7):939-946. [CrossRef]
  • 235. Fretland ÅA, Dagenborg VJ, Bjørnelv GMW, et al. Laparoscopic versus open resection for colorectal liver metastases: the OSLOCOMET randomized controlled trial. Ann Surg. 2018;267(2):199-207. [CrossRef]
  • 236. Zhou Y, Xiao Y, Wu L, Li B, Li H. Laparoscopic liver resection as a safe and efficacious alternative to open resection for colorectal liver metastasis: a meta-analysis. BMC Surg. 2013;13:44-. [CrossRef]
  • 237. Luo LX, Yu ZY, Bai YN. Laparoscopic hepatectomy for liver metastases from colorectal cancer: a meta-analysis. J Laparoendosc Adv Surg Tech A. 2014;24(4):213-222. [CrossRef]
  • 238. Wei M, He Y, Wang J, Chen N, Zhou Z, Wang Z. Laparoscopic versus open hepatectomy with or without synchronous colectomy for colorectal liver metastasis: a meta-analysis. PLoS One. 2014;9(1): e87461. [CrossRef]
  • 239. Baltatzis M, Chan AK, Jegatheeswaran S, Mason JM, Siriwardena AK. Colorectal cancer with synchronous hepatic metastases: systematic review of reports comparing synchronous surgery with sequential bowel-first or liver-first approaches. Eur J Surg Oncol. 2016;42(2):159-165. [CrossRef]
  • 240. Shubert CR, Habermann EB, Bergquist JR, et al. A NSQIP review of major morbidity and mortality of synchronous liver resection for colorectal metastasis stratified by extent of liver resection and type of colorectal resection. J Gastrointest Surg. 2015;19(11):1982-1994. [CrossRef]
  • 241. Cucchetti A, Cappelli A, Ercolani G, et al. Selective internal radiation therapy (SIRT) as conversion therapy for unresectable primary liver malignancies. Liver Cancer. 2016;5(4):303-311. [CrossRef]
  • 242. Abulkhir A, Limongelli P, Healey AJ, et al. Preoperative portal vein embolization for major liver resection: a meta-analysis. Ann Surg. 2008;247(1):49-57. [CrossRef]
  • 243. Fusai G, Davidson BR. Strategies to increase the resectability of liver metastases from colorectal cancer. Dig Surg. 2003;20(6): 481-496. [CrossRef]
  • 244. Sandström P, Røsok BI, Sparrelid E, et al. ALPPS improves resectability compared with conventional two-stage hepatectomy in patients with advanced colorectal liver metastasis: results from a Scandinavian multicenter randomized controlled trial (LIGRO trial). Ann Surg. 2018;267(5):833-840. [CrossRef]
  • 245. Lang H, Baumgart J, Mittler J. Associating liver partition and portal vein ligation for staged hepatectomy in the treatment of colorectal liver metastases: current scenario. Dig Surg. 2018;35(4): 294-302. [CrossRef]
  • 246. Vigano L, Darwish SS, Rimassa L, et al. Progression of colorectal liver metastases from the end of chemotherapy to resection: a new contraindication to surgery? Ann Surg Oncol. 2018;25(6):1676-1685. [CrossRef]
  • 247. Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2013;14(12):1208-1215. [CrossRef]
  • 248. Benoist S, Brouquet A, Penna C, et al. Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol. 2006;24(24):3939-3945. [CrossRef]
  • 249. Tani K, Shindoh J, Akamatsu N, et al. Management of disappearing lesions after chemotherapy for colorectal liver metastases: relation between detectability and residual tumors. J Surg Oncol. 2018;117(2):191-197. [CrossRef]
  • 250. Nozawa H, Ishihara S, Kawai K, et al. Conversion to resection in patients receiving systemic chemotherapy for unresectable and/or Metastatic Colorectal Cancer-Predictive Factors and Prognosis. Clin Colorectal Cancer. 2018;17(1):e91-e97. [CrossRef]
  • 251. Maeda Y, Shinohara T, Nagatsu A, Futakawa N, Hamada T. Long-term outcomes of conversion hepatectomy for initially unresectable colorectal liver metastases. Ann Surg Oncol. 2016; 23(suppl 2):S242-S248. [CrossRef]
  • 252. Rama N, Monteiro A, Bernardo JE, Eugénio L, Antunes MJ. Lung metastases from colorectal cancer: surgical resection and prognostic factors. Eur J Cardiothorac Surg. 2009;35(3):444-449. [CrossRef]
  • 253. Gonzalez M, Robert JH, Halkic N, et al. Survival after lung metastasectomy in colorectal cancer patients with previously resected liver metastases. World J Surg. 2012;36(2):386-391. [CrossRef]
  • 254. Guerrera F, Mossetti C, Ceccarelli M, et al. Surgery of colorectal cancer lung metastases: analysis of survival, recurrence and re-surgery. J Thorac Dis. 2016;8(7):1764-1771. [CrossRef]
  • 255. Gonzalez M, Gervaz P. Risk factors for survival after lung metastasectomy in colorectal cancer patients: systematic review and meta-analysis. Future Oncol. 2015;11(2)(suppl):31-33. [CrossRef]
  • 256. Gonzalez M, Poncet A, Combescure C, Robert J, Ris HB, Gervaz P. Risk factors for survival after lung metastasectomy in colorectal cancer patients: a systematic review and meta-analysis. Ann Surg Oncol. 2013;20(2):572-579. [CrossRef]
  • 257. Onaitis MW, Petersen RP, Haney JC, et al. Prognostic factors for recurrence after pulmonary resection of colorectal cancer metastases. Ann Thorac Surg. 2009;87(6):1684-1688. [CrossRef]
  • 258. Silberfein EJ, Kattepogu KM, Hu CY, et al. Long-term survival and recurrence outcomes following surgery for distal rectal cancer. Ann Surg Oncol. 2010;17(11):2863-2869. [CrossRef]
  • 259. Gómez-España MA, Gallego J, González-Flores E, et al. SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer (2018). Clin Transl Oncol. 2019;21(1):46-54. [CrossRef]
  • 260. Adam R, de Gramont A, Figueras J, et al. Managing synchronous liver metastases from colorectal cancer: a multidisciplinary international consensus. Cancer Treat Rev. 2015;41(9):729-741. [CrossRef]
  • 261. Kontovounisios C, Tan E, Pawa N, et al. The selection process can improve the outcome in locally advanced and recurrent colorectal cancer: activity and results of a dedicated multidisciplinary colorectal cancer centre. Colorectal Dis. 2017;19(4):331-338. [CrossRef]
  • 262. Verwaal VJ, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21(20):3737-3743. [CrossRef]
  • 263. Elias D, Delperro JR, Sideris L, et al. Treatment of peritoneal carcinomatosis from colorectal cancer: impact of complete cytoreductive surgery and difficulties in conducting randomized trials. Ann Surg Oncol. 2004;11(5):518-521. [CrossRef]
  • 264. Cashin PH, Mahteme H, Spång N, et al. Cytoreductive surgery and intraperitoneal chemotherapy versus systemic chemotherapy for colorectal peritoneal metastases: a randomised trial. Eur J Cancer. 2016;53:155-162. [CrossRef]
  • 265. Quenet F, Elias D, Roca L, et al. A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7. J Clin Oncol. 2018;36(18_ suppl):LBA3503-LBA. [CrossRef]
  • 266. Guren MG, Undseth C, Rekstad BL, et al. Reirradiation of locally recurrent rectal cancer: a systematic review. Radiother Oncol. 2014;113(2):151-157. [CrossRef]
  • 267. Haddock MG. Irradiation of very locally advanced and recurrent rectal cancer. Semin Radiat Oncol. 2016;26(3):226-235. [CrossRef]
  • 268. Rowland A, Dias MM, Wiese MD, et al. Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer. Br J Cancer. 2015;112(12):1888-1894. [CrossRef]
  • 269. Pietrantonio F, Petrelli F, Coinu A, et al. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis. Eur J Cancer. 2015;51(5):587-594. [CrossRef]
  • 270. Tournigand C, André T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004;22(2):229-237. [CrossRef]
  • 271. Colucci G, Gebbia V, Paoletti G, et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell’Italia Meridionale. J Clin Oncol. 2005;23(22):4866-4875. [CrossRef]
  • 272. Yamazaki K, Nagase M, Tamagawa H, et al. Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G). Ann Oncol. 2016;27(8):1539-1546. [CrossRef]
  • 273. Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluor ourac il-le ucovo rin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol. 2004;22(7):1209-1214. [CrossRef]
  • 274. Hanna N, Woods C, Zheng Z, Onukwugha E, Seal BS, Mullins CD. Survival benefit associated with the number of chemo thera py/bi ologi c treatment lines in 5,129 metastatic colon cancer patients. J Clin Oncol. 2014;32(3_suppl):559-. [CrossRef]
  • 275. Kishi Y, Zorzi D, Contreras CM, et al. Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases. Ann Surg Oncol. 2010;17(11):2870-2876. [CrossRef]
  • 276. Welsh FKS, Tilney HS, Tekkis PP, John TG, Rees M. Safe liver resection following chemotherapy for colorectal metastases is a matter of timing. Br J Cancer. 2007;96(7):1037-1042. [CrossRef]
  • 277. Venook AP, Niedzwiecki D, Innocenti F, et al. Impact of primary (1°) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): analysis of CALGB/SWOG 80405 (Alliance). J Clin Oncol. 2016;34(15_suppl):3504-. [CrossRef]
  • 278. Cremolini C, Loupakis F, Antoniotti C, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the openlabel, phase 3 TRIBE study. Lancet Oncol. 2015;16(13):1306-1315. [CrossRef]
  • 279. Tomasello G, Petrelli F, Ghidini M, Russo A, Passalacqua R, Barni S. FOLFOXIRI plus bevacizumab as conversion therapy for patients with initially unresectable metastatic colorectal cancer: a systematic review and pooled analysis. JAMA Oncol. 2017;3(7): e170278. [CrossRef]
  • 280. Cremolini C, Antoniotti C, Lonardi S, et al. Activity and safety of cetuximab plus modified FOLFOXIRI followed by maintenance with cetuximab or bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a randomized Phase 2 clinical trial. JAMA Oncol. 2018;4(4):529-536. [CrossRef]
  • 281. Modest DP, Martens UM, Riera-Knorrenschild J, et al. FOLFOXIRI plus panitumumab as first-line treatment of RAS wild-type metastatic colorectal cancer: the randomized, open-label, Phase II VOLFI study (AIO KRK0109). J Clin Oncol. 2019;37(35):3401-3411. [CrossRef]
  • 282. Geissler M, Riera-Knorrenschild J, Tannapfel A, et al. mFOLFOXIRI + panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild- type metastatic colorectal cancer m(CRC): a randomized phase II VOLFI trial of the AIO (AIOKRK0109). J Clin Oncol. 2018;36(15_suppl):3509-. [CrossRef]
  • 283. Kopetz S, McDonough SL, Lenz H-J, et al. Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAFmutant metastatic colorectal cancer (SWOG S1406). J Clin Oncol. 2017;35:3505.
  • 284. Nasti G, Piccirillo MC, Izzo F, et al. Neoadjuvant FOLFIRI+bevacizumab in patients with resectable liver metastases from colorectal cancer: a phase 2 trial. Br J Cancer. 2013;108(8):1566- 1570. [CrossRef]
  • 285. Primrose J, Falk S, Finch-Jones M, et al. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial. Lancet Oncol. 2014;15(6):601-611. [CrossRef]
  • 286. Portier G, Elias D, Bouche O, et al. Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol. 2006;24(31):4976-4982. [CrossRef]
  • 287. Mitry E, Fields AL, Bleiberg H, et al. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol. 2008;26(30):4906-4911. [CrossRef]
  • 288. Renaud S, Schaeffer M, Falcoz PE, et al. Perioperative bevacizumab improves survival following lung metastasectomy for colorectal cancer in patients harbouring v-Ki-ras2 Kirsten rat sarcoma viral oncogene homologue exon 2 codon 12 mutationsdagger. Eur J Cardiothorac Surg. 2017;51(2):255-262. [CrossRef]
  • 289. Le DT, Uram JN, Wang H, et al. Programmed death-1 blockade in mismatch repair deficient colorectal cancer. J Clin Oncol. 2016;34:103-104.
  • 290. Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017;18(9): 1182-1191. [CrossRef]
  • 291. Koopman M, Kortman GA, Mekenkamp L, et al. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Br J Cancer. 2009;100(2):266-273. [CrossRef]
  • 292. Lochhead P, Kuchiba A, Imamura Y, et al. Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. J Natl Cancer Inst. 2013;105(15):1151-1156. [CrossRef]
  • 293. Venderbosch S, Nagtegaal ID, Maughan TS, et al. Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the Cairo, CAIRO2, COIN, and FOCUS studies. Clin Cancer Res. 2014;20(20):5322-5330. [CrossRef]
  • 294. Kim MJ, Kim SJ, Park SC, et al. Adjuvant radiotherapy for the treatment of stage IV rectal cancer after curative resection: a propensity score-matched analysis and meta-analysis. Medicine. 2016;95(47):e4925. [CrossRef]
  • 295. Agas RAF, Co LBA, Jacinto JCKM, et al. Neoadjuvant radiotherapy versus no radiotherapy for Stage IV rectal cancer: a systematic review and meta-analysis. J Gastrointest Cancer. 2018;49(4):389- 401. [CrossRef]
  • 296. Lin JK, Lee LK, Chen WS, et al. Concurrent chemoradiotherapy followed by metastasectomy converts to survival benefit in stage IV rectum cancer. J Gastrointest Surg. 2012;16(10):1888-1896. [CrossRef]
  • 297. Bisschop C, van Dijk TH, Beukema JC, et al. Short-course radiotherapy followed by neoadjuvant bevacizumab, capecitabine, and oxaliplatin and subsequent radical treatment in primary Stage IV rectal cancer: long-term results of a Phase II study. Ann Surg Oncol. 2017;24(9):2632-2638. [CrossRef]
  • 298. Buckley H, Wilson C, Ajithkumar T. High-dose-rate brachytherapy in the management of operable rectal cancer: a systematic review. Int J Radiat Oncol Biol Phys. 2017;99(1):111-127. [CrossRef]
  • 299. Haddock MG. Intraoperative radiation therapy for colon and rectal cancers: a clinical review. Radiat Oncol. 2017;12(1):11. [CrossRef]
  • 300. Haddock MG, Miller RC, Nelson H, et al. Combined modality therapy including intraoperative electron irradiation for locally recurrent colorectal cancer. Int J Radiat Oncol Biol Phys. 2011;79(1):143-150. [CrossRef]
  • 301. Gunderson LL, Nelson H, Martenson JA, et al. Locally advanced primary colorectal cancer: intraoperative electron and external beam irradiation +/− 5-FU. Int J Radiat Oncol Biol Phys. 1997;37(3):601- 614. [CrossRef]
  • 302. Dubois JB, Bussieres E, Richaud P, et al. Intra-operative radiotherapy of rectal cancer: results of the French multi-institutional randomized study. Radiother Oncol. 2011;98(3):298-303. [CrossRef]
  • 303. Cameron MG, Kersten C, Vistad I, Fosså S, Guren MG. Palliative pelvic radiotherapy of symptomatic incurable rectal cancer - a systematic review. Acta Oncol. 2014;53(2):164-173. [CrossRef]
  • 304. Takeda A, Sanuki N, Tsurugai Y, Oku Y, Aoki Y. Stereotactic body radiotherapy for patients with oligometastases from colorectal cancer: risk-adapted dose prescription with a maximum dose of 83-100 Gy in five fractions. J Radiat Res. 2016;57(4):400-405. [CrossRef]
  • 305. Jin W, Burke AM, Rashid A, Marshall J, Unger KR. Does stereotactic body radiation therapy have a role in oligoprogressive metastatic colorectal cancer? J Clin Oncol. 2018;36(4_suppl):755-. [CrossRef]
  • 306. Scorsetti M, Arcangeli S, Tozzi A, et al. Is stereotactic body radiation therapy an attractive option for unresectable liver metastases? A preliminary report from a phase 2 trial. Int J Radiat Oncol Biol Phys. 2013;86(2):336-342. [CrossRef]
  • 307. Palma DA, Haasbeek CJ, Rodrigues GB, et al. Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): study protocol for a randomized phase II trial. BMC Cancer. 2012;12:305. [CrossRef]
  • 308. Palma D. Stereotactic ablative radiation therapy for the comprehensive treatment of oligometastatic tumors (SABR-COMET): results of a randomized trial. Int J Radiat Oncol • Biology • Physics. 2018;102:S3-S4.
  • 309. Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27(8):1386-1422. [CrossRef]
  • 310. Ruers T, Van Coevorden F, Punt CJ, et al. Local treatment of unresectable colorectal liver metastases: results of a randomized Phase II trial. J Natl Cancer Inst. 2017;109(9). [CrossRef]
  • 311. Bhutiani N, Akinwande O, Martin RC, 2nd. Efficacy and toxicity of hepatic intra-arterial drug-eluting (irinotecan) bead (DEBIRI) therapy in irino tecan -refr actor y unresectable colorectal liver metastases. World J Surg. 2016;40(5):1178-1190. [CrossRef]
  • 312. Liu DM, Thakor AS, Baerlocher M, et al. A review of conventional and drug-eluting chemoembolization in the treatment of colorectal liver metastases: principles and proof. Future Oncol. 2015;11(9):1421- 1428. [CrossRef]
  • 313. Martin RC, 2nd, Scoggins CR, Schreeder M, et al. Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis. Cancer. 2015;121(20):3649-3658. [CrossRef]
  • 314. Fiorentini G, Aliberti C, Tilli M, et al. Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study. Anticancer Res. 2012;32(4): 1387-1395.
  • 315. Hendlisz A, Van den Eynde M, Peeters M, et al. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J Clin Oncol. 2010;28(23):3687-3694. [CrossRef]
  • 316. Wasan HS, Gibbs P, Sharma NK, et al. First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. Lancet Oncol. 2017;18(9):1159-1171. [CrossRef]
  • 317. Braat MN, Samim M, van den Bosch MAAJ, Lam MGEH. The role of (90)Y -radi oembo lizat ion in downstaging primary and secondary hepatic malignancies: a systematic review. Clin Transl Imaging. 2016;4:283-295. [CrossRef]
  • 318. Justinger C, Kouladouros K, Gärtner D, et al. Liver resection after selective internal radiotherapy (SIRT): proof of concept, initial survival, and safety. J Surg Oncol. 2015;112(4):436-442. [CrossRef]
  • 319. Rex DK, Boland CR, Dominitz JA, et al. Colorectal cancer screening: recommendations for physicians and patients from the U.S. Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2017;153(1):307-323. [CrossRef]
  • 320. Kaminski MF, Thomas-Gibson S, Bugajski M, et al. Performance measures for lower gastrointestinal endoscopy: a European Society of Gastrointestinal Endoscopy (ESGE) Quality Improvement Initiative. Endoscopy. 2017;49(4):378-397. [CrossRef]
  • 321. Bucci C, Rotondano G, Hassan C, et al. Optimal bowel cleansing for colonoscopy: split the dose! A series of meta-analyses of controlled studies. Gastrointest Endosc. 2014;80(4):566-576.e2. [CrossRef]
  • 322. US Preventive Services Task Force, Bibbins-Domingo K, Grossman DC, et al. Screening for colorectal cancer: US Preventive Services Task Force recommendation statement. JAMA. 2016;315(23): 2564-2575. [CrossRef]
  • 323. Wolf AMD, Fontham ETH, Church TR, et al. Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society. CA Cancer J Clin. 2018;68(4):250-281. [CrossRef]
  • 324. Parés D, Duncan J, Dudding T, Phillips RK, Norton C. Investigation to predict faecal continence in patients undergoing reversal of a defunctioning stoma (Porridge enema test). Colorectal Dis. 2008;10(4):379-385. [CrossRef]
  • 325. Saing S, Haywood P, Duncan JK, Ma N, Cameron AL, Goodall S. Cost-effective imaging for resectability of liver lesions in colorectal cancer: an economic decision model. ANZ J Surg. 2018;88(6): E507-E511-e11. [CrossRef]
  • 326. Kye BH, Cho HM. Overview of radiation therapy for treating rectal cancer. Ann Coloproctol. 2014;30(4):165-174. [CrossRef] 327. Kumar A, Merali A, Pond GR, Zbuk K. Fertility risk discussions in young patients diagnosed with colorectal cancer. Curr Oncol. 2012;19(3):155-159. [CrossRef]
  • 328. Schover LR, Rybicki LA, Martin BA, Bringelsen KA. Having children after cancer. A pilot survey of survivors’ attitudes and experiences. Cancer. 1999;86(4):697-709. [CrossRef]
  • 329. Schover LR, Brey K, Lichtin A, Lipshultz LI, Jeha S. Knowledge and experience regarding cancer, infertility, and sperm banking in younger male survivors. J Clin Oncol. 2002;20(7):1880-1889. [CrossRef]
  • 330. Lim JF, Tjandra JJ, Hiscock R, Chao MW, Gibbs P. Preoperative chemoradiation for rectal cancer causes prolonged pudendal nerve terminal motor latency. Dis Colon Rectum. 2006;49(1):12-19. [CrossRef]
  • 331. Paquette IM, Varma MG, Kaiser AM, Steele SR, Rafferty JF, The American Society of Colon and Rectal Surgeons. The American Society of Colon and Rectal Surgeons’ Clinical practice guideline for the treatment of fecal incontinence. Dis Colon Rectum. 2015;58(7): 623-636. [CrossRef]
  • 332. Conroy T, Lamfichekh N, Etienne P, et al. Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: final results of PRODIGE 23 phase III trial, a UNICANCER GI trial. J Clin Oncol. 2020; 38(15_suppl):4007-4007. [CrossRef]
APA Aytac E, BALIK E, Ozer L, Baca B, Kapran Y, Taşkın O, Oyan B, Abacioglu U, Gonenc M, bolukbasi y, Cil B, Baran B, Aygun C, YILDIZ M, Unal K, B, YALTI M, Ozbek U, attila t, Tozun A, gürses b, Erdamar S, ER O, Bese N, Bilge O, Ceyhan G, mandel n, SELEK U, YAKICIER M, Kayserili H, Saruç M, Ozben V, Esen E, Ozoran E, Vardareli E, Guner L, Hamzaoglu I, buğra d, karahasanoğlu t (2022). Optimizing the Personalized Care for the Management of Rectal Cancer: A Consensus Statement. , 627 - 663. 10.5152/tjg.2022.211103
Chicago Aytac Erman,BALIK Emre,Ozer Leyla,Baca Bilgi,Kapran Yersu,Taşkın Orhun Çığ,Oyan Basak,Abacioglu Ufuk,Gonenc Murat,bolukbasi yasemin,Cil Barbaros,Baran Bulent,Aygun Cem,YILDIZ M. ERDEM,Unal Kemal, Burçak,YALTI M TUNÇ,Ozbek Ugur,attila tan,Tozun Ayse Nurdan,gürses bengi,Erdamar Sibel,ER OZLEM,Bese Nuran,Bilge Orhan,Ceyhan Güralp Onur,mandel nil,SELEK UGUR,YAKICIER Mustafa Cengiz,Kayserili Hülya,Saruç Murat,Ozben Volkan,Esen Eren,Ozoran Emre,Vardareli Erkan,Guner Levent,Hamzaoglu Ismail,buğra dursun,karahasanoğlu tayfun Optimizing the Personalized Care for the Management of Rectal Cancer: A Consensus Statement. (2022): 627 - 663. 10.5152/tjg.2022.211103
MLA Aytac Erman,BALIK Emre,Ozer Leyla,Baca Bilgi,Kapran Yersu,Taşkın Orhun Çığ,Oyan Basak,Abacioglu Ufuk,Gonenc Murat,bolukbasi yasemin,Cil Barbaros,Baran Bulent,Aygun Cem,YILDIZ M. ERDEM,Unal Kemal, Burçak,YALTI M TUNÇ,Ozbek Ugur,attila tan,Tozun Ayse Nurdan,gürses bengi,Erdamar Sibel,ER OZLEM,Bese Nuran,Bilge Orhan,Ceyhan Güralp Onur,mandel nil,SELEK UGUR,YAKICIER Mustafa Cengiz,Kayserili Hülya,Saruç Murat,Ozben Volkan,Esen Eren,Ozoran Emre,Vardareli Erkan,Guner Levent,Hamzaoglu Ismail,buğra dursun,karahasanoğlu tayfun Optimizing the Personalized Care for the Management of Rectal Cancer: A Consensus Statement. , 2022, ss.627 - 663. 10.5152/tjg.2022.211103
AMA Aytac E,BALIK E,Ozer L,Baca B,Kapran Y,Taşkın O,Oyan B,Abacioglu U,Gonenc M,bolukbasi y,Cil B,Baran B,Aygun C,YILDIZ M,Unal K, B,YALTI M,Ozbek U,attila t,Tozun A,gürses b,Erdamar S,ER O,Bese N,Bilge O,Ceyhan G,mandel n,SELEK U,YAKICIER M,Kayserili H,Saruç M,Ozben V,Esen E,Ozoran E,Vardareli E,Guner L,Hamzaoglu I,buğra d,karahasanoğlu t Optimizing the Personalized Care for the Management of Rectal Cancer: A Consensus Statement. . 2022; 627 - 663. 10.5152/tjg.2022.211103
Vancouver Aytac E,BALIK E,Ozer L,Baca B,Kapran Y,Taşkın O,Oyan B,Abacioglu U,Gonenc M,bolukbasi y,Cil B,Baran B,Aygun C,YILDIZ M,Unal K, B,YALTI M,Ozbek U,attila t,Tozun A,gürses b,Erdamar S,ER O,Bese N,Bilge O,Ceyhan G,mandel n,SELEK U,YAKICIER M,Kayserili H,Saruç M,Ozben V,Esen E,Ozoran E,Vardareli E,Guner L,Hamzaoglu I,buğra d,karahasanoğlu t Optimizing the Personalized Care for the Management of Rectal Cancer: A Consensus Statement. . 2022; 627 - 663. 10.5152/tjg.2022.211103
IEEE Aytac E,BALIK E,Ozer L,Baca B,Kapran Y,Taşkın O,Oyan B,Abacioglu U,Gonenc M,bolukbasi y,Cil B,Baran B,Aygun C,YILDIZ M,Unal K, B,YALTI M,Ozbek U,attila t,Tozun A,gürses b,Erdamar S,ER O,Bese N,Bilge O,Ceyhan G,mandel n,SELEK U,YAKICIER M,Kayserili H,Saruç M,Ozben V,Esen E,Ozoran E,Vardareli E,Guner L,Hamzaoglu I,buğra d,karahasanoğlu t "Optimizing the Personalized Care for the Management of Rectal Cancer: A Consensus Statement." , ss.627 - 663, 2022. 10.5152/tjg.2022.211103
ISNAD Aytac, Erman vd. "Optimizing the Personalized Care for the Management of Rectal Cancer: A Consensus Statement". (2022), 627-663. https://doi.org/10.5152/tjg.2022.211103
APA Aytac E, BALIK E, Ozer L, Baca B, Kapran Y, Taşkın O, Oyan B, Abacioglu U, Gonenc M, bolukbasi y, Cil B, Baran B, Aygun C, YILDIZ M, Unal K, B, YALTI M, Ozbek U, attila t, Tozun A, gürses b, Erdamar S, ER O, Bese N, Bilge O, Ceyhan G, mandel n, SELEK U, YAKICIER M, Kayserili H, Saruç M, Ozben V, Esen E, Ozoran E, Vardareli E, Guner L, Hamzaoglu I, buğra d, karahasanoğlu t (2022). Optimizing the Personalized Care for the Management of Rectal Cancer: A Consensus Statement. Turkish Journal of Gastroenterology, 33(8), 627 - 663. 10.5152/tjg.2022.211103
Chicago Aytac Erman,BALIK Emre,Ozer Leyla,Baca Bilgi,Kapran Yersu,Taşkın Orhun Çığ,Oyan Basak,Abacioglu Ufuk,Gonenc Murat,bolukbasi yasemin,Cil Barbaros,Baran Bulent,Aygun Cem,YILDIZ M. ERDEM,Unal Kemal, Burçak,YALTI M TUNÇ,Ozbek Ugur,attila tan,Tozun Ayse Nurdan,gürses bengi,Erdamar Sibel,ER OZLEM,Bese Nuran,Bilge Orhan,Ceyhan Güralp Onur,mandel nil,SELEK UGUR,YAKICIER Mustafa Cengiz,Kayserili Hülya,Saruç Murat,Ozben Volkan,Esen Eren,Ozoran Emre,Vardareli Erkan,Guner Levent,Hamzaoglu Ismail,buğra dursun,karahasanoğlu tayfun Optimizing the Personalized Care for the Management of Rectal Cancer: A Consensus Statement. Turkish Journal of Gastroenterology 33, no.8 (2022): 627 - 663. 10.5152/tjg.2022.211103
MLA Aytac Erman,BALIK Emre,Ozer Leyla,Baca Bilgi,Kapran Yersu,Taşkın Orhun Çığ,Oyan Basak,Abacioglu Ufuk,Gonenc Murat,bolukbasi yasemin,Cil Barbaros,Baran Bulent,Aygun Cem,YILDIZ M. ERDEM,Unal Kemal, Burçak,YALTI M TUNÇ,Ozbek Ugur,attila tan,Tozun Ayse Nurdan,gürses bengi,Erdamar Sibel,ER OZLEM,Bese Nuran,Bilge Orhan,Ceyhan Güralp Onur,mandel nil,SELEK UGUR,YAKICIER Mustafa Cengiz,Kayserili Hülya,Saruç Murat,Ozben Volkan,Esen Eren,Ozoran Emre,Vardareli Erkan,Guner Levent,Hamzaoglu Ismail,buğra dursun,karahasanoğlu tayfun Optimizing the Personalized Care for the Management of Rectal Cancer: A Consensus Statement. Turkish Journal of Gastroenterology, vol.33, no.8, 2022, ss.627 - 663. 10.5152/tjg.2022.211103
AMA Aytac E,BALIK E,Ozer L,Baca B,Kapran Y,Taşkın O,Oyan B,Abacioglu U,Gonenc M,bolukbasi y,Cil B,Baran B,Aygun C,YILDIZ M,Unal K, B,YALTI M,Ozbek U,attila t,Tozun A,gürses b,Erdamar S,ER O,Bese N,Bilge O,Ceyhan G,mandel n,SELEK U,YAKICIER M,Kayserili H,Saruç M,Ozben V,Esen E,Ozoran E,Vardareli E,Guner L,Hamzaoglu I,buğra d,karahasanoğlu t Optimizing the Personalized Care for the Management of Rectal Cancer: A Consensus Statement. Turkish Journal of Gastroenterology. 2022; 33(8): 627 - 663. 10.5152/tjg.2022.211103
Vancouver Aytac E,BALIK E,Ozer L,Baca B,Kapran Y,Taşkın O,Oyan B,Abacioglu U,Gonenc M,bolukbasi y,Cil B,Baran B,Aygun C,YILDIZ M,Unal K, B,YALTI M,Ozbek U,attila t,Tozun A,gürses b,Erdamar S,ER O,Bese N,Bilge O,Ceyhan G,mandel n,SELEK U,YAKICIER M,Kayserili H,Saruç M,Ozben V,Esen E,Ozoran E,Vardareli E,Guner L,Hamzaoglu I,buğra d,karahasanoğlu t Optimizing the Personalized Care for the Management of Rectal Cancer: A Consensus Statement. Turkish Journal of Gastroenterology. 2022; 33(8): 627 - 663. 10.5152/tjg.2022.211103
IEEE Aytac E,BALIK E,Ozer L,Baca B,Kapran Y,Taşkın O,Oyan B,Abacioglu U,Gonenc M,bolukbasi y,Cil B,Baran B,Aygun C,YILDIZ M,Unal K, B,YALTI M,Ozbek U,attila t,Tozun A,gürses b,Erdamar S,ER O,Bese N,Bilge O,Ceyhan G,mandel n,SELEK U,YAKICIER M,Kayserili H,Saruç M,Ozben V,Esen E,Ozoran E,Vardareli E,Guner L,Hamzaoglu I,buğra d,karahasanoğlu t "Optimizing the Personalized Care for the Management of Rectal Cancer: A Consensus Statement." Turkish Journal of Gastroenterology, 33, ss.627 - 663, 2022. 10.5152/tjg.2022.211103
ISNAD Aytac, Erman vd. "Optimizing the Personalized Care for the Management of Rectal Cancer: A Consensus Statement". Turkish Journal of Gastroenterology 33/8 (2022), 627-663. https://doi.org/10.5152/tjg.2022.211103